Meghmani Organics Reports Q3 FY26 Revenue of ₹484.9 Crore; EBITDA at ₹51.5 Crore
03 February 2026, Mumbai: Meghmani Organics Limited announced its standalone financial results for the third quarter ended 31 December 2025 (Q3 FY26).
Read More
Meghmani Organics Limited
Meghmani Organics Limited begins commercial production of Cyfluthrin, Spiromesifen in Dahej, India
05 October 2022, New Delhi: Meghmani Organics Limited (MOL) began the commercial production of Cyfluthrin and Spiromesifen, with initial capacity of
Read More